Trial Profile

Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Pemetrexed; Taxanes
Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

20 Dec 2024 Status changed from active, no longer recruiting to discontinued due to pandemic-related slow accrual
18 Apr 2024 Planned End Date changed from 1 Nov 2023 to 31 Dec 2024.
22 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com